Communiqués Genprex, Inc.

Actions

GNPX

US3724462037

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
1,97 ^USD	+0,51 %		-3,90 %	-78,59 %

15/05	Genprex, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
14/05	Genprex administre la dose au premier patient dans le cadre de l'étude clinique Acclaim-3 sur la thérapie immunogène Reqorsa en association avec Tecentriq pour le traitement du cancer du poumon à petites cellules	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Genprex : 2024 Genprex Stockholder Letter	14:39	PU
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	10/04	AQ
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System	03/04	AQ
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	20/03	AQ
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers	13/03	AQ
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting	07/03	AQ
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators	08/02	AQ
Genprex to Present at Upcoming BIO CEO and Investor Conference	07/02	AQ
Genprex to Present at BIO-Europe 2023 Conference	02/11	AQ
AACR-NCI-EORTC International Conference 2023 – Completion of Acclaim-1 Dose Escalation: Recommended Phase 2 Dose of Quaratusugene Ozeplasmid Gene Therapy and Osimertinib	13/10/23	PU
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC	21/09/23	GL
Genprex Granted FDA Orphan Drug Designation for REQORSA Immunogene Therapy for the Treatment of Small Cell Lung Cancer	11/08/23	AQ
CapitalGainsReport Penny Stock Bounce List: EPAZ, ARDS, FRTX, GNPX	24/07/23	AQ
Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	20/07/23	AQ
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh	19/07/23	AQ
IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc.	06/07/23	AQ
BigTime Penny Stocks: Stocks to Watch: GNPX, MRES, DVLP, EMGE	29/06/23	AQ
BigTime Penny Stocks: Potential Breakout Stocks - Watchlist (GNPX, CLNV, CNBX, WOEN)	02/06/23	AQ
BigTime Penny Stocks: Rapid Growth in Gene Therapy Market (GNPX, LEAS;RWOD, VYGR, AVRO)	01/06/23	AQ
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA in Combination with Tagrisso in Advanced Non-Small Cell Lung Cancer	31/05/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Genprex, Inc.

Actions

GNPX

US3724462037

Communiqués

Filtres